Karyopharm Therapeutics, a pharmaceutical company, has raised $20.5 million in venture capital, according to a new filing by the company with the Securities and Exchange Commission.

Founded in 2008, Karyopharm Therapeutics is a clinical-stage pharmaceutical company focused on discovery and development of novel drugs for the treatment of cancer, inflammation and other diseases related to cell proliferation.

Our lead products are first in class, oral Selective Inhibitors of Nuclear Export (SINE), which irreversibly block nuclear-cytoplasmic transport mediated by Exportin-1 (XPO1, also called CRM1).